key: cord-0920223-hq2ygrcc
authors: Petrone, Linda; Petruccioli, Elisa; Vanini, Valentina; Cuzzi, Gilda; Gualano, Gina; Vittozzi, Pietro; Nicastri, Emanuele; Maffongelli, Gaetano; Grifoni, Alba; Sette, Alessandro; Ippolito, Giuseppe; Migliori, Giovanni Battista; Palmieri, Fabrizio; Goletti, Delia
title: Coinfection of tuberculosis and COVID-19 limits the ability to in vitro respond to SARS-CoV-2
date: 2021-03-10
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.02.090
sha: 6ba0ef460dfb66a6933b054b9e437ea800c5f438
doc_id: 920223
cord_uid: hq2ygrcc

OBJECTIVES: The interaction of COVID-19 and tuberculosis (TB) are still poor characterized. Here we evaluated the immune response specific for M. tuberculosis (Mtb) and SARS-CoV-2 using a whole-blood-based assay-platform in COVID-19 patients either with TB or latent TB infection (LTBI). METHODS: We evaluated IFN-γ level in plasma from whole-blood stimulated with Mtb antigens in the Quantiferon-Plus format or with peptides derived from SARS-CoV-2 spike protein, Wuhan-Hu-1 isolate (CD4-S). RESULTS: We consecutively enrolled 63 COVID-19, 10 TB-COVID-19 and 11 LTBI-COVID-19 patients. IFN-γ response to Mtb-antigens was significantly associated to TB status and therefore it was higher in TB-COVID-19 and LTBI-COVID-19 patients compared to COVID-19 patients (p ≤ 0.0007). Positive responses against CD4-S were found in 35/63 COVID-19 patients, 7/11 LTBI-COVID-19 and only 2/10 TB-COVID-19 patients. Interestingly, the responders in the TB-COVID-19 group were less compared to COVID-19 and LTBI-COVID-19 groups (p = 0.037 and 0.044, respectively). Moreover, TB-COVID-19 patients showed the lowest quantitative IFN-γ response to CD4-S compared to COVID-19-patients (p = 0.0336) and LTBI-COVID-19 patients (p = 0.0178). CONCLUSIONS: Our data demonstrate that COVID-19 patients either TB or LTBI have a low ability to build an immune response to SARS-CoV-2 while retaining the ability to respond to Mtb-specific antigens.

The World Health Organization (WHO) estimated in 2019, 10 million tuberculosis (TB) cases with 1.6 million deaths worldwide (WHO, 2020a). Lung is the most frequent TB localization, but any organ can be affected (Goletti et al., 2018) . Since 2020, COronaVIrus Disease-2019 (COVID-19) caused by Severe Acute Respiratory Syndrome-CoronaVirus-2 (SARS-CoV-2) spread globally with around 111 million cases reported (WHO, 2020b) . There is evidence, that COVID-19 pandemic worsened TB epidemic globally due to TBservices fragmentation and additional pressures on health systems by COVID-19 resulting in weakening of the National TB programs (Migliori et al., 2020) .

COVID-19 is characterized by several clinical features ranging from an asymptomatic state to severe forms with immune dysregulation that may lead to immune pathology (Falasca et al., 2020) . As for TB, lung is the most frequent disease localization, and in a minority of patients, it may lead to a rapid respiratory failure and death (Gandhi et Interferon (IFN)-γ is mainly produced by the CD4 T -cells whereas IL-12 and TNF-α by the antigen presenting J o u r n a l P r e -p r o o f cells. IFN-γ secretion enhances the macrophage microbicidal mechanisms, regulate Th17-cells and the tissue damage whereas TNF-α has been associated with granuloma integrity (Cantini et al., 2017) .

Concomitant Mtb-specific and SARS-CoV-2-specific response is not yet fully understood. Recently, it has been reported a similarity of the immune signatures associated with COVID-19 clinical severity and the spectrum of asymptomatic-and symptomatic-TB (Sheerin et al., 2020) .

Still undescribed are the biological effects of the interaction of the two infections that may recall the concept of 'cursed duet' that in the past was used to describe TB and HIV coinfection (Goletti et al., 1996) .

Therefore, in this study we evaluated the impact of SARS-CoV-2 and Mtb concomitant infections on the immune response specific for each pathogen, using a whole-blood-based assay platform. 

Six hundred microliter of whole-blood were stimulated or not with CD4-S at 0.1 µg/mL and Staphylococcal Enterotoxin B as positive control at 200 ng/mL. CD4-S concentration was selected based on dose-titration experiments previously reported . Plasma was harvested after over-night stimulation at 37°C (5% CO2) and stored at -80° until use.

QFT -Plus assay was performed and results analysed according to the reported criteria (http://www.quantiferon.com/irm/content/PI/QFT/PLUS/2PK-Elisa/UK.pdf).

Plasma IFN-γ level was evaluated by ELISA (www.quantiFERON.com). Results were analyzed by a QuantiFERON-Plus Analysis Software (www.quantiFERON.com) and values were subtracted from the unstimulated control.

Data were analyzed using SPSS software ( Table 1 shows the clinical and demographical information.

Within the COVID-19-patients, 4 showed comorbidities: 2 had diabetes, 1 had multiple sclerosis (MS) and 1 chronic renal failure. TB-COVID-19-patients had pulmonary TB (n=5, 50%), or extrapulmonary TB (n=1, 10%) either culture-or molecular-confirmed; 4 (40%) patients had pulmonary and extrapulmonary TB and among them 2 had clinical pulmonary TB ( Table 1 ). Time of diagnosis of TB vs COVID-19 is detailed in Table 1 .

Lymphocyte counts were the highest in COVID-19, followed by LTBI-COVID-19 and TB-COVID-19 (medians:

1.5, 1.35, 0.97, respectively); however, the difference among these groups was not significant (p=0.39, Table   1 ). Finally, severity stage is shown in Table 1 for all the three groups.

NO-COVID-19-subjects were HD (n=5) or had echinococcosis (n=1) or bacterial pneumonia (n=2). All NO-COVID-19 scored QFT -Plus negative and all of them tested negative for SARS-CoV-2 specific IgG. In subjects with a serology result available, the testing was performed concomitantly (or within a week) with the wholeblood test.

All COVID-19-patients were tested for QFT -Plus. Within the COVID-19-patients, 59 (93.7%) had a negative QFT -Plus result and 4 (6.3%) scored indeterminate (Table 1) . Interestingly, only 5 (50%) TB-COVID-19patients scored positive to QFT -plus and the remaining patients scored either negative (n=4, 40%) or indeterminate (n=1, 10%). Patients with a positive result had concordant TB1 and TB2 results (Table 1) . By contrast, the majority of LTBI-COVID-19-patients scored QFT -Plus positive (n=9, 81.8%). In these patients, concordant TB1 and TB2 results were found in 7/9, 1 patient had a positive TB1 score and 1 patient had a positive TB2 result (Table 1) .

J o u r n a l P r e -p r o o f IFN-γ response to QFT -Plus antigens TB1 and TB2 was evaluated in all the subjects enrolled. As expected the IFN-γ level in COVID-19-patients was significantly lower compared to TB-COVID-19 and LTBI-COVID-19patients in response to TB1 (p=0.0007 and p<0.0001, respectively; Figure 1A ) and TB2 (p=0.0002 and p<0.0001, respectively; Figure 1B) . IFN-γ level in response to TB1 or TB2 did not significantly differ between COVID-19 and NO-COVID-19-subjects. (Table 1) . Interestingly, the number of responders in the TB-COVID-19 group was lower compared to COVID-19 only and LTBI-COVID-19 groups (Table 1) . Then, we stratified the no-responders to CD4-S based on the COVID-19 disease.

Interestingly, within the COVID-19-patients, we observed a trend of absence of a viral-specific response along with the severity grade of the disease. Differently, among the TB-COVID, no trend was observed (80% were no responders) (Table 1) . Moreover, as shown in Figure 1C , although not significant, TB-COVID-19-patients showed the lowest IFN-γ levels in response to CD4-S compared to COVID-19-patients and to LTBI-COVID-19patients. CD4-S-specific response was significantly higher in COVID-19-patients compared to NO-COVID-19subjects (p=0.0015, Figure 1C ). No significant differences were found in response to the mitogen among the groups evaluated ( Figure 1D ). We also evaluated cortisone therapy impact on the ability to respond to CD4-S in COVID-19-patients, TB-COVID-19-patients and LTBI-COVID-19-patients. No significant differences were found between patients that received cortisone and those not treated with steroids (p=0.19; p=0.053; p=0.89 respectively). Interestingly, among patients receiving cortisone, none of the TB-COVID-19 responded to CD4-S, whereas 45.5% of the COVID-19-patients and 66.7% of the LTBI-COVID-19 responded, although no significant difference was found (Table 1) .

In this study, we investigated for the first time to our knowledge, the biological effects of the interaction of COVID-19 and TB, evaluating the immune response specific for SARS-CoV-2 and Mtb, using a whole-bloodbased assay platform. Our data demonstrate that TB significantly reduces the SARS-CoV-2-specific response in coinfected TB-COVID-19-patients. is characterized by lymphopenia that is considered a marker of the disease severity (Tan et al., 2020; Lanini et al., 2020) . Further, immunosuppressive drugs may be used to treat COVID-19-patients (Cantini et al., 2020) .

Despite these assumptions, our data demonstrate that COVID-19-patients either TB or LTBI retain the ability to respond to Mtb-specific antigens.

In contrast, coinfected TB-COVID-19-patients have a low chance to build an immune response to SARS-CoV-2. Interestingly, these patients had the lowest lymphocyte counts compared to the other two groups. The Limitation of this work should be accounted. The small size and the heterogeneity of the groups examined hampered us to fully characterize the relationship between COVID-19 and TB. Moreover, the antigen used to evaluate the SARS-CoV-2 response, shows a moderate sensitivity for COVID-19 identification.

In conclusion, we demonstrated that TB impairs the ability to mount a SARS-CoV-2-specific immune response in co-infected subjects. These evidences, if confirmed in larger studies, may be useful in evaluating the management and diagnostic algorithms of TB and COVID-19 co-infection.

Study conception and design: DG. 

Risk factors for COVID-19 death in a population cohort study from the Western Cape Province, South Africa

Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review

Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics

Measles -The epidemiology of elimination

Postmortem Findings in Italian Patients With COVID-19: A Descriptive Full Autopsy Study of Cases With and Without Comorbidities

COVID-19 in a patient with active tuberculosis: A rare case-report

Mild or Moderate Covid-19

Following the development of a CD4 T cell response in vivo: from activation to memory formation

Can we predict tuberculosis cure? What tools are available?

Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation

A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

COVID-19 disease-Temporal analyses of complete blood count parameters over course of illness, and relationship to patient demographics and management outcomes in survivors and non-survivors: A longitudinal descriptive cohort study

Worldwide Effects of Coronavirus Disease Pandemic on Tuberculosis Services

Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells

Tuberculosis, COVID-19 and migrants: Preliminary analysis of deaths occurring in 69 patients from two cohorts

Concurrent cavitary pulmonary tuberculosis and COVID-19 pneumonia with in vitro immune cell anergy

Epidemic and pandemic viral infections: impact on tuberculosis and the lung. A consensus by the World Association for Infectious Diseases and Immunological Disorders (WAidid)

A whole blood test to measure SARS-CoV-2-specific response in COVID-19 patients

Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity

Systematic evaluation of transcriptomic disease risk and diagnostic biomarker overlap between COVID-19 and tuberculosis: a patient-level meta-analysis

Clinical characteristics of COVID-19 and active tuberculosis co-infection in an Italian reference hospital

Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases

On tuberculosis and COVID-19 co-infection

Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study

TB/COVID-19 Global Study Group. TB and COVID-19 co-infection: rationale and aims of a global study

Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome

Examining the Complex Relationship Between Tuberculosis and Other Infectious Diseases in Children

Clinical management of COVID-19. Interim guidance

Functional impairment during post-acute COVID-19 phase: Preliminary finding in 56 patients